Navigation Links
Transgenomic, Inc. Reports Third Quarter 2008 Results
Date:10/29/2008

OMAHA, Neb., Oct. 29 /PRNewswire-FirstCall/ -- Transgenomic, Inc. (OTC Bulletin Board: TBIO) today announced financial results for the quarter ended September 30, 2008. The Company's financial results are presented in the tables that follow.

Third Quarter 2008

Net sales from continuing operations were $5.4 million during the third quarter of 2008, compared to $5.2 million during the comparable period of 2007. Gross profit from continuing operations was $2.9 million or 54 percent during the third quarter of 2008 compared to $2.7 million or 51 percent during the comparable period of 2007. Operating expenses from continuing operations were $3.4 million during the third quarter of 2008 compared to $4.1 million during the same period of 2007. The increase in gross profits and decrease in operating expenses reflect the Company's efforts to control costs while leveraging stable revenues from the instrument and consumables business to continue growing and expanding the Molecular Clinical Reference Laboratory and Pharmacogenomics Services Laboratory businesses.

The Company reported a net loss of $499,000 or $0.01 per share for the third quarter of 2008 as compared to a net loss of $1.3 million or $0.03 per share for the third quarter of 2007.

Cash and cash equivalents totaled $4.8 million at September 30, 2008.

Nine Months Ended September 30, 2008

The Company reported a net loss of $276,000 or $0.01 per share for the nine months ended September 30, 2008, compared to a net loss of $2.3 million or $0.05 per share during the comparable period of 2007. Net losses in 2008 resulted from continuing operations. The 2007 net loss was comprised of a loss from continuing operations of $2.4 million or $0.05 per share and income from discontinued operations of $66,000 or $0.00 per share.

Net sales from continuing operations were $17.9 million for the nine months ended September 30, 2008, compared to $16.7 million during the comparable period of 2007. The increase in net sales was attributable to revenue growth and expanding services from its laboratory businesses.

Gross profit from continuing operations was $10.3 million or 58 percent for the nine months ended September 30, 2008, compared to $8.8 million or 53 percent in 2007. Operating expenses from continuing operations were $10.7 million for the nine months ended September 30, 2008, compared to $12.3 million during the comparable period of 2007. Operating expenses for the nine months ended September 30, 2008 included $1.3 million of restructuring charges.

The company used cash flows from operations of $472,000 for the nine months ended September 30, 2008, compared to cash flows used in operations of $2.7 million during the same period in 2007. The increase in gross profit, decrease in operating expenses and lower cash flow use reflect the new management team's focus on conservative spending and revenue growth.

Comment and Outlook

Craig Tuttle, President and Chief Executive Officer of Transgenomic, commented, "We are pleased to announce 7% revenue growth year-to-date, driven by the strength of our expanding Laboratory Services businesses. We reported a net loss in the third quarter of 2008 after two consecutive quarters of profitability. Historically our third quarter has been slower for our instrument and service businesses due to summer laboratory closures in Europe and heavy vacation schedules in the U.S. We remain confident in our financial performance, which reflects our efforts to conserve cash while building our Laboratory Services businesses and maintaining our instrument revenues. We expect to continue expanding services offered within our laboratories as we evaluate in-licensing, collaboration and acquisition opportunities that have the potential to create additional value and accelerate growth."

Earnings Call

Company management will discuss third quarter 2008 financial results via teleconference on Wednesday, October 29th, at 5:00 p.m. Eastern Time. To access the call via telephone, dial 800-862-9098 or 785-424-1051. The Company will also host a live broadcast of the call over the Internet. To listen to the webcast, investors should log on to the Company's Investor Relations web page at http://www.transgenomic.com/events.asp?id=6 and follow the instructions provided. An archived recording of the conference call will be available and can be accessed via the web using the same link listed above for 14 days after the call. Investors can also listen to a replay via telephone until 11:59 p.m. Eastern Time on Wednesday, November 12, 2008. Simply dial 888-566-0849 or 402-220-0428 from any telephone.

About Transgenomic

Transgenomic is a global biotechnology company that provides unique products and services for automated high sensitivity genetic variation and mutation analysis. Their offerings include systems, products, discovery and laboratory testing services to the academic and medical research, clinical laboratory and pharmaceutical markets in the fields of pharmacogenomics and personalized medicine. Specific offerings include WAVE(R) DHPLC Systems, related consumables and assay kits, cytogenetics automated systems, Transgenomic Molecular Clinical Reference Laboratory and Pharmacogenomics Research Services. Transgenomic's two laboratory services divisions utilize these technologies and expertise to provide a menu of mutation scanning tests for over 700 cancer-associated genes and more than 60 validated diagnostic tests to meet the needs of pharmaceutical and biotech companies, research and clinical laboratories, physicians and patients. For more information about the innovative systems, products and services offered by Transgenomic, please visit: http://www.transgenomic.com.

Transgenomic Cautionary Statements

Certain statements in this press release constitute "forward-looking statements" of Transgenomic within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements include, but are not limited to, those with respect to management's current views and estimates of future economic circumstances, industry conditions, company performance and financial results, including the ability of the Company to grow its involvement in the diagnostic products and services markets. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in Transgenomic's reports to the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Accordingly, the company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release. All information in this press release is as of the date of the release and Transgenomic does not undertake any duty to update this information, including any forward-looking statements, unless required by law.

Transgenomic, Inc.

Summary Financial Results

Unaudited Condensed Consolidated Statements of Operations

(Dollars in thousands except per share data)

Three Months Ended Nine Months Ended

September 30, September 30,

2008 2007 2008 2007

NET SALES $5,367 $5,151 $17,869 $16,645

COST OF GOODS SOLD 2,448 2,500 7,570 7,872

Gross profit 2,919 2,651 10,299 8,773

OPERATING EXPENSES:

Selling, general

and administrative 2,757 2,672 8,824 8,719

Research and

development 684 720 1,816 2,270

Restructuring costs - 681 8 1,305

3,441 4,073 10,648 12,294

LOSS FROM OPERATIONS (522) (1,422) (349) (3,521)

OTHER INCOME (EXPENSE):

Interest income 22 75 80 215

Other, net 14 4 13 8

Gain on sale of investment - - - 938

36 79 93 1,161

LOSS BEFORE INCOME TAXES (486) (1,343) (256) (2,360)

INCOME TAX EXPENSE 13 6 20 25

LOSS FROM CONTINUING

OPERATIONS (499) (1,349) (276) (2,385)

INCOME FROM DISCONTINUED

OPERATIONS, NET OF TAX - - - 66

NET LOSS $(499) $(1,349) $(276) $(2,319)

BASIC AND DILUTED

LOSS PER SHARE:

From continuing

operations $(0.01) $(0.03) $(0.01) $(0.05)

From discontinued

operations - 0.00 - 0.00

$(0.01) $(0.03) $(0.01) $(0.05)

BASIC AND DILUTED

WEIGHTED AVERAGE

SHARES OUTSTANDING 49,189,672 49,189,672 49,189,672 49,189,672

Transgenomic, Inc.

Summary Financial Results

Unaudited Condensed Consolidated Statements of Cash Flows

(Dollars in thousands)

Nine Months Ended

September 30,

2008 2007

NET CASH FLOWS USED IN OPERATING ACTIVITIES (472) (2,652)

NET CASH FLOWS PROVIDED BY (USED IN)

INVESTING ACTIVITIES (254) 3,279

EFFECT OF FOREIGN CURRENCY EXCHANGE RATE

CHANGES ON CASH (210) 48

NET CHANGE IN CASH AND CASH EQUIVALENTS (936) 675

CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD 5,723 5,868

CASH AND CASH EQUIVALENTS AT END OF PERIOD $4,787 $6,543

Transgenomic, Inc.

Summary Financial Results

Condensed Consolidated Balance Sheets

(Dollars in thousands)

(Unaudited)

September 30, December 31,

2008 2007

ASSETS

CURRENT ASSETS:

Cash and cash equivalents $4,787 $5,723

Accounts receivable (net of allowances

for bad debts of $501 and $703, respectively) 4,944 5,095

Inventories 4,921 4,586

Prepaid expenses and other current assets 727 759

Total current assets 15,379 16,163

PROPERTY AND EQUIPMENT, NET 1,276 1,579

OTHER ASSETS:

Goodwill 638 638

Other assets, net 657 710

$17,950 $19,090

LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES:

Accounts payable $816 $1,245

Other accrued expenses 2,526 3,152

Accrued compensation 752 450

Total current liabilities 4,094 4,847

OTHER LONG TERM LIABILITIES 141 141

Total liabilities 4,235 4,988

STOCKHOLDERS' EQUITY 13,715 14,102

$17,950 $19,090


'/>"/>
SOURCE Transgenomic, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Transgenomic, Inc. Forms Scientific Advisory Board
2. Transgenomic, Inc. Reports Second Quarter 2007 Results
3. Neurocrine Biosciences Reports Third Quarter 2008 Results
4. Cephalon Reports Another Strong Quarter
5. Cepheid Reports Third Quarter Revenue of $44.9 Million
6. BioTrends Releases TreatmentTrends(TM): Nephrology and Renal Dietitians, Two Syndicated Reports Providing Continuing Insight into the Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
7. Masimo Reports Third Quarter 2008 Financial Results
8. Abaxis Reports Record Revenues and Operating Income for the Second Quarter of Fiscal 2009
9. Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis
10. BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza
11. International Drug & Explosive Detection Firm Identa Corp Releasing: Jant Pharmacal Corporation Reports Successful Market Penetration of the Accutest(R) IDenta Co-brand in the United States and Oversees
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... ... to an early access program for SmartBiome -- a novel metagenomic deep-sequencing ... simultaneous specific enrichment and detection of hundreds of different genes. The selective ...
(Date:12/6/2016)... Laurel, NJ (PRWEB) , ... December 06, 2016 ... ... white paper on December 1, 2016 asking the Federal Drug Administration (FDA) to ... the study of OA, OARSI is concerned about the growing population of OA ...
(Date:12/6/2016)... -- According to a new market research report "Microfluidics ... Application (Genomics, Proteomics, Capillary Electrophoresis, POC, Clinical, Environmental, Drug Delivery) - ... projected to reach USD 8.78 Billion by 2021 from USD 3.65 ... period (2016 to 2021). Continue Reading ... ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... development of precision treatments for neurodegenerative diseases, today announced the validated monoclonal ... the direct neurotoxic effect of prion-like forms of Amyloid beta (Aß) in ...
Breaking Biology Technology:
(Date:6/22/2016)... June 22, 2016  The American College of Medical Genetics ... Executive Magazine as one of the fastest-growing trade shows ... at the Bellagio in Las Vegas . ... percentage of growth in each of the following categories: net ... and number of attendees. The 2015 ACMG Annual Meeting was ...
(Date:6/21/2016)... British Columbia , June 21, 2016 /PRNewswire/ ... appointed to the new role of principal product ... been named the director of customer development. Both ... NuData,s chief technical officer. The moves reflect NuData,s ... teams in response to high customer demand and ...
(Date:6/15/2016)... , June 15, 2016 ... market report titled "Gesture Recognition Market by Application Market - Global ... 2016 - 2024". According to the report, the  global ... billion in 2015 and is estimated to grow ... 48.56 billion by 2024.  Increasing application ...
Breaking Biology News(10 mins):